

ASX Release

Addendum to Company Presentation released on 2 December 2024

ADELAIDE, 23rd December 2024: Anatara Lifesciences Ltd (ASX: ANR or Anatara or “the Company”), a developer of evidence-based solutions for human health disorders, provides details of the assumptions that supported Slide 30 from the recent Company Presentation.

The following “Peer Comparison Slide” should have preceded Slide 30 in the presentation released on 2nd December 2024.

Peer Comparison

JUNIOR ASX LISTED COMPANIES OPERATING IN
HEALTHCARE AND WELLNESS SECTOR

On the following page are several ASX listed companies that could form a peer comparison to Anatara Lifesciences on one or more of the following basis:

- They are micro-cap ASX listed companies that are in the junior healthcare or wellness sectors, of which Anatara Lifesciences is too.
- Some of the companies are developing or have products in the gastrointestinal health space, similar to Anatara Lifesciences.
- Some of the companies are developing or have products that are over the counter (OTC), similar to Anatara Lifesciences.
- The Company's are listed purely for illustrative purposes and to help the reader understand what similar companies or competition there exists to Anatara Lifesciences on the Australian Securities Exchange (ASX).



For convenience , the updated slide referred to as Slide 30 from the presentation is included and follows:



Peer Comparison

Company	Stock Code	Company Focus	Market Capitalisation*	Share Price*	Cash Receipts (FY24)	Net Operating Cash (FY24)
Anatara Lifesciences	ANR:ASX	Anatara is focused on the validation of gastrointestinal products including the clinical validation of GaRP, aimed at restoring and maintaining gut health	\$11.6m	\$0.056	Nil	(\$1.45m)
Nutritional Growth Solutions	NGS:ASX	Nutritional Growth Solutions has developed patented nutritional supplement formulae focusing on the growth development of children	\$5.7m	\$0.044	\$1.25m ¹	(\$1.3m) ²
The Calmer Co International	CCO:ASX	Calmer Co (formerly Fiji Kava) is developing and producing natural solutions for relaxation, anxiety and sleep through a range of functional food and beverages	\$17.6m	\$0.008	\$2.5m ³	(\$1.6m) ⁴
Immuron	IMC:ASX	Immuron produces OTC medication (Travelan & Protectyn) reducing the risk of traveler's diarrhea and gastro-intestinal disorders.	\$17.1m	\$0.074	\$4.9m ⁵	(\$6.9m) ⁶
Bioxyne	BXN:ASX	Bioxyne has developed and globally distributes their patented probiotic strain focusing on immunity and gastrointestinal health and a subsidiary focused on medical cannabis.	\$26.6m	\$0.013	\$9.6m ⁷	(\$13.3m) ⁸
Microba Life Sciences	MAP:ASX	Microba provides microbiome testing for gastrointestinal diseases and is developing therapeutics in inflammatory bowel disease, cancer Immunotherapy & autoimmune diseases	\$74m	\$0.165	\$12.1m ⁹	(\$19.9m) ¹⁰
Vita Life Sciences	VLS:ASX	Vita Life Sciences develops and distributes OTC medicines, as well as complementary and alternative medicines, dietary supplements and health foods	\$118m	\$2.10	\$39.4m ¹¹ (1H24 only)	\$4.2m ¹² (1H24 only)

Source: Iress 25th November 2024, ASX company announcements

1 & 2: <https://cdn-api.marktidigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02846954-6A1223246>
3 & 4: <https://cdn-api.marktidigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02846668-6A1223151>
5 & 6: <https://cdn-api.marktidigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02846453-3A649475>
7 & 8: <https://cdn-api.marktidigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02846857-2A1545148>
9 & 10: <https://cdn-api.marktidigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02845374-2A1544373>
11 & 12: <https://cdn-api.marktidigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02843168-3A648774>

This announcement was authorised for release on the ASX by Anatara Lifesciences Ltd Executive Chair, Dr. David Brookes, with Board approval.

For more information please contact:

Dr. David Brookes
Chair, Anatara Lifesciences Ltd
+61 (0) 411 712 579
dbrookes@anatara.com

Dirk van Dissel
Candour Advisory – Investor Relations
+61 (0) 408 326 367
dirk@candouradvisory.com.au

About Anatara Lifesciences Ltd

Anatara Lifesciences Ltd (ASX:ANR) is developing and commercialising innovative, evidence-based health products where there is significant unmet need. Anatara is focused on building a pipeline of human health products with a particular focus on conditions that involve the complexity of the gastrointestinal tract. Underlying this product development program is our commitment to delivering real outcomes for patients and strong value for our shareholders.



Disclaimer

The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN 145 239 872 (Company). In preparing this presentation, the Company did not take into account the investment objectives, financial situation, and particular needs of any particular investor. Further advice should be obtained from a professional investment adviser before taking any action on any information dealt with in the presentation. Those acting upon any information without advice do so entirely at their own risk. Whilst this presentation is based on information from sources which are considered reliable, no representation or warranty, express or implied, is made or given by or on behalf of the Company, any of its directors, or any other person about the accuracy, completeness or fairness of the information or opinions contained in this presentation. No responsibility or liability is accepted by any of them for that information or those opinions or for any errors, omissions, misstatements (negligent or otherwise) or for any communication written or otherwise, contained or referred to in this presentation. Neither the Company nor any of its directors, officers, employees, advisers, associated persons or subsidiaries are liable for any direct, indirect or consequential loss or damage suffered by any person as a result of relying upon any statement in this presentation or any document supplied with this presentation, or by any future communications in connection with those documents and all of those losses and damages are expressly disclaimed. Any opinions expressed reflect the Company's position at the date of this presentation and are subject to change.

Anatara Lifesciences Limited

Registered Office

C/-PERKS Level 8,81 Flinders Street, Adelaide SA 5000

Email info@anatara.com | Website anataralifesciences.com

